Application No.	Applicant(s)	
09/963,693	RUVKUN ET AL.	
Examiner	Art Unit	
Sumesh Kaushal Ph.D.	1633	
(OR REMAINS) CLOSED in th or other appropriate communic	the correspondence address is application. If not included cation will be mailed in due course. THIS ject to withdrawal from issue at the initiative	
the Examiner.		
der 35 U.S.C. § 119(a)-(d) or (been received. been received in Application Numerts have been received in		
of this communication to file a r ENT of this application.	eply complying with the requirements	
tted. Note the attached EXÀMI s reason(s) why the oath or de	NER'S AMENDMENT or NOTICE OF eclaration is deficient.	
t be submitted. on's Patent Drawing Review (1 Amendment / Comment or in 84(c)) should be written on the one header according to 37 CFR 1	the Office action of frawings in the front (not the back) of	
7. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.		
6. ☐ Interview Sumi Paper No./Ma 8), 7. ⊠ Examiner's Am	il Date	
	Examiner Sumesh Kaushal Ph.D. ars on the cover sheet with a (OR REMAINS) CLOSED in the or other appropriate communic GHTS. This application is subpand MPEP 1308. the Examiner. der 35 U.S.C. § 119(a)-(d) or (abeen received). been received. been received in Application Not the communication to file and ENT of this application. tted. Note the attached EXAMI is reason(s) why the oath or deat be submitted. on's Patent Drawing Review (18). Amendment / Comment or in 184(c)) should be written on the communication to file and the header according to 37 CFR 185 and 185	

Art Unit: 1633

EXAMINER'S AMENDMENT

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Karen Elbing on 07/25/05.

The application has been amended as follows:

IN THE CLAIMS

1. (currently amended) A method of diagnosing an impaired glucose tolerance condition, obesity, or a propensity thereto in a patient mammal, said method comprising analyzing the level of mammalian PTEN expression or activity in a sample isolated from said patient mammal, whereby an increase in said level of PTEN expression or activity relative to a control sample is an indication of an impaired glucose tolerance condition, obesity, or a propensity thereto.

2. (canceled)

- 3. (previously presented) The method of claim 1, wherein said level of PTEN expression or activity is analyzed by measuring PTEN lipid phosphatase activity.
 - 4. (canceled)
 - 5. (canceled)
 - 6. (canceled)
 - 7. (new) The method of claim 1, wherein the said mammal is a human.

IN THE SPECIFICATION

Page 1, line 7, insert now U.S. Patent No. 6,861,256, after "filed December 3,1998,".

Art Unit: 1633

REASONS FOR ALLOWANCE

The following is an examiner's statement of reasons for allowance:

Claims 1, 3 and 7 are free of prior art of record. The prior art does not teach or suggest a method of diagnosing an impaired glucose tolerance condition, obesity or a propensity thereto in a patient by analyzing the level of PTEN expression or activity (PTEN lipid phosphatase activity) in a sample isolated from a patient, wherein an increase in the PTEN expression or activity relative to a control sample is indication of an impaired glucose tolerance condition, obesity or a propensity thereto.

The PTEN is a mammalian homolog of C.elegans *daf-18*, which modulates insulin-signaling pathway. The closest prior art made of record and not relied upon is considered pertinent to applicant's disclosure:- *Ogg et al. The C. elegans PTEN homolog, DAF-18, acts in the insulin receptor-like metabolic signaling pathway. Mol Cell. 2(6):887-893, 1998 (reference of record).*

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Sumesh Kaushal Ph.D. whose telephone number is 571-272-0769. The examiner can normally be reached on Mon-Fri. from 9AM-5PM. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Dave Nguyen can be reached on 571-272-0731.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to (571) 272-0547. For all other customer support, please call the USPTO Call Center (UCC) at 800-786-9199. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Patent applicants with problems or questions regarding electronic images that can be viewed in the Patent Application Information Retrieval system (PAIR) can now contact the USPTO's Patent Electronic Business Center (Patent EBC) for assistance. Representatives are available to answer your questions daily from 6 am to midnight (EST). The toll free number is (866) 217-9197. When calling please have your application serial or patent number, the type of document you are having an image problem with, the number of pages and the specific nature of the problem. The Patent Electronic Business Center will notify applicants of the resolution of the problem within 5-7 business days. Applicants can also check PAIR to confirm that the problem has been corrected. The USPTO's Patent Electronic Business Center is a complete service center supporting all patent business on the Internet. The USPTO's PAIR system provides Internet-based access to patent application status and history information. It also enables applicants to view the scanned images of their own application file folder(s) as well as general patent information available to the public.

Sumushlih.
SUMESH KAUSHAL
PATENT EXAMINER